Tepotinib plus paclitaxel for MET-altered stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether tepotinib combined with paclitaxel can treat stomach or gastroesophageal (GEJ) cancer that has spread and has specific MET gene changes. It may help by blocking the MET pathway that can drive tumor growth after standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 19 or older and able to sign informed consent
- Your cancer has MET changes: MET amplification or MET exon 14 skipping mutation found in tumor tissue testing
- For phase 2: your stomach/GEJ cancer must have progressed after first chemotherapy with a “fluoropyrimidine” medicine
- You generally need good body strength (ECOG 0–1) and enough blood/organ function for treatment
- You must not have active brain metastases causing symptoms or unstable findings (leptomeningeal spread is excluded)
- You must not have had certain recent treatments, prior c-MET inhibitor therapy, or other key exclusions (like recent chemo, major heart problems, or uncontrolled infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a new combination of two drugs—one targets EGFR on cancer cells, and the other boosts your immune system—for people with advanced stomach or GEJ cancer whose tumors are EGFR-positive and have already tried one prior chemotherapy.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial is testing a new form of the chemotherapy drug docetaxel (called albumin-bound docetaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this version of the drug works better or has fewer side effects.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests whether adding an immunotherapy drug (adebrelimab) with or without another targeted drug (apatinib) to standard chemotherapy is more effective for advanced stomach cancer. It aims to shrink tumors and improve outcomes for people who haven't had prior treatment for advanced disease.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.